全球診斷放射性同位素市場

到 2030 年，全球診斷放射性同位素市場規模將達到 56 億美元

全球診斷放射性同位素市場規模預計在2024年為42億美元，到2030年將達到56億美元，在2024-2030年的分析期間內，複合年成長率為5.0%。Technetium-99m是本報告分析的細分市場之一，預計其複合年成長率為4.1%，到分析期結束時將達到13億美元。鉈-201細分市場的複合年成長率預計在分析期間為4.1%。

美國市場規模估計為 11 億美元，中國市場預期複合年成長率為 7.7%

美國診斷放射性同位素市場規模預計2024年達到11億美元。作為世界第二大經濟體的中國，預計在2030年將達到11億美元，在分析期內（2024-2030年）的複合年成長率為7.7%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為2.5%和4.9%。在歐洲，預計德國的複合年成長率為3.2%。

全球診斷放射性同位素市場—主要趨勢與促進因素摘要

為什麼診斷放射性同位素對於現代醫學影像至關重要？

診斷性放射性同位素在現代醫療保健中發揮著至關重要的作用，它使臨床醫生能夠以高特異性和微創性的方式觀察和評估器官、組織和細胞過程的功能。這些放射性同位素用於核子醫學成像技術，例如正電子發射斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT)，提供傳統成像方式（例如 CT 和 MRI）無法捕獲的代謝和功能資訊。例如，在腫瘤學中，用於 FDG-PET 掃描的氟-18 等診斷性放射性同位素有助於識別惡性腫瘤、對癌症進行分期、監測治療效果並檢測早期復發。在心臟病學中，Technetium-99m 等同位素用於心肌灌注成像，以評估冠狀動脈疾病和心臟功能。神經系統應用包括阿茲海默症、癲癇和帕金森氏症的成像，可以在結構異常出現之前很久就識別出分子變化。診斷放射性同位素因其能夠即時洞察生理功能而備受推崇，這對於早期發現和精準治療計劃至關重要。隨著個人化醫療的日益普及，這些藥物擴大與標靶治療治療相結合，構成了將診斷和治療監測整合在一個連續體中的診療方法的基礎。

科技進步如何提升基於放射性同位素的診斷能力？

快速的技術創新正在擴大醫療保健領域診斷放射性同位素的功效、安全性和範圍。迴旋加速器和核子反應爐技術的發展提高了主要同位素的生產效率和可用性，解決了全球供應挑戰並減少了對老化核子反應爐的依賴。混合 PET/CT 和 PET/MRI 掃描儀等成像硬體的增強實現了解剖數據和功能數據的融合，從而提高了診斷準確性並實現了更精確的疾病定位。軟體主導的改進，包括人工智慧和先進的影像重建演算法，有助於減少掃描時間、輻射暴露和假陽性，同時提高影像解析度和量化能力。此外，放射性藥物化學已經發展到可以設計同位素與高度特異性的生物標的（例如癌症生物標記和澱粉樣斑塊）結合的程度，從而實現高度靈敏、特異性疾病的成像診斷。使用放射性同位素標記示蹤劑的伴隨診斷技術正在與標靶治療同步開發，透過為合適的患者提供合適的治療，改善治療效果並降低成本。放射性藥物製備和品管的自動化使基於同位素的診斷更具可重複性和擴充性，從而實現更廣泛的臨床應用。這些技術進步正在推動基於放射性同位素的診斷策略朝更準確、個人化和高效的方向發展。

為什麼全球醫療保健系統對放射性同位素成像的臨床需求不斷增加？

由於慢性病發病率上升、人口老化以及早期準確診斷的重要性日益提升，全球醫療保健系統對診斷用放射性同位素的臨床需求激增。在腫瘤學領域，全球癌症發生率的快速成長推動了對正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 成像的需求，這些成像嚴重依賴放射性同位素進行腫瘤檢測、分期和治療監測。同樣，心血管疾病盛行率的上升也推動了對銣-82 和鉈-201 等同位素進行核應力測試和心肌灌注成像的需求。在神經病學領域，阿茲海默症和帕金森氏症等神經退化性疾病的發生率上升，正在擴大能夠在分子層面上早期檢測病理變化的放射性同位素的應用。此外，精準醫療和標靶治療方法的廣泛應用需要伴隨診斷（通常涉及放射性同位素標記藥物）來確認疾病的存在並預測治療反應。隨著小型移動成像系統和簡化放射性通訊協定的發展，診斷放射性同位素也擴大被應用於門診病人和流動醫療環境。在新興市場，核子醫學基礎設施的改善和醫療保健支出的增加正在加速放射性同位素診斷的普及。隨著臨床醫生和政策制定者重視及時、非侵入性和準確的診斷，預計未來幾年放射性同位素的臨床需求將大幅成長。

加速全球診斷放射性同位素市場成長的關鍵促進因素是什麼？

診斷放射性同位素市場的成長受到醫療、技術、監管和經濟等多種因素的共同驅動，這些因素反映了分子影像在精準醫療中日益成長的作用。其中一個最重要的促進因素是全球癌症、心血管疾病和神經退化性疾病負擔的不斷加重，早期準確的診斷可以顯著改善患者的預後。此外，持續向基於價值的醫療保健模式轉變，也鼓勵醫療保健提供者採用能夠更早指導治療決策、減少不必要程序並最佳化治療結果的診斷方法。迴旋加速器和放射性藥物生產能力​​的擴張正在改善同位素的可及性，而對核子醫學基礎設施的持續投資正在開拓新的市場，尤其是在亞太地區和拉丁美洲。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構正在加速放射性藥物的核准途徑，尤其是那些作為新型療法伴隨診斷工具而開發的藥物。此外，製藥公司與診斷技術開發商之間的策略聯盟正在推動治療診斷學領域的發展，該領域使用放射性同位素進行標靶治療的選擇和監測。教育措施和臨床培訓計畫也有助於縮小核醫學人才缺口，進一步刺激招募。隨著全球醫療保健系統走向早期療育、降低醫療成本和個人化患者照護，診斷放射性同位素已成為下一代醫療圖像影像和疾病管理的關鍵推動因素。

部分

放射性同位素類型（Technetium-99m、銪-201、鎵-67、碘-123、FDG、銣-82、其他放射性同位素類型）、診斷放射性同位素（SPECT、PET、 BETA發射體）、用途（診斷、治療）、最終用途（醫院、專科診所、診斷中心、學術用途/研究機構、其他最終用途）

受訪公司範例（43家值得關注的公司）

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging SpA
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion（Canada）Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Diagnostic Radioisotopes Market to Reach US$5.6 Billion by 2030

The global market for Diagnostic Radioisotopes estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Technetium-99m, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Thallium-201 segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.7% CAGR

The Diagnostic Radioisotopes market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Diagnostic Radioisotopes Market - Key Trends & Drivers Summarized

Why Are Diagnostic Radioisotopes Indispensable in Modern Medical Imaging?

Diagnostic radioisotopes play a critical role in contemporary healthcare by enabling clinicians to visualize and assess the function of organs, tissues, and cellular processes with high specificity and minimal invasiveness. These radioactive substances are used in nuclear medicine imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which provide metabolic and functional information that traditional imaging modalities like CT and MRI cannot capture. For example, in oncology, diagnostic radioisotopes like Fluorine-18 (used in FDG-PET scans) help identify malignant tumors, determine cancer staging, monitor treatment efficacy, and detect early recurrence. In cardiology, isotopes such as Technetium-99m are used in myocardial perfusion imaging to evaluate coronary artery disease and cardiac function. Neurological applications include imaging for Alzheimer’s disease, epilepsy, and Parkinson’s disease, where molecular changes can be identified long before structural anomalies appear. Diagnostic radioisotopes are prized for their ability to provide real-time insights into physiological function, which is crucial for early detection and precision treatment planning. As personalized medicine gains traction, these agents are increasingly used in tandem with targeted therapies, forming the foundation of theranostic approaches that combine diagnostics with treatment monitoring in a single continuum.

How Are Technological Advancements Enhancing the Capabilities of Radioisotope-Based Diagnostics?

Rapid technological innovations are expanding the efficacy, safety, and reach of diagnostic radioisotope applications in healthcare. Developments in cyclotron and reactor technologies have improved the production efficiency and availability of key isotopes, addressing global supply challenges and reducing reliance on aging nuclear reactors. Enhanced imaging hardware, such as hybrid PET/CT and PET/MRI scanners, now allows for the fusion of anatomical and functional data, yielding superior diagnostic accuracy and enabling more precise localization of disease. Software-driven improvements, including artificial intelligence and advanced image reconstruction algorithms, are helping reduce scan times, radiation exposure, and false positives while enhancing image resolution and quantification capabilities. Moreover, radiopharmaceutical chemistry has advanced to the point where isotopes can be engineered to bind to highly specific biological targets, such as cancer biomarkers or amyloid plaques, resulting in highly sensitive and disease-specific imaging. Companion diagnostics using radiolabeled tracers are being developed alongside targeted therapies to ensure the right patients receive the right treatment, improving therapeutic outcomes and reducing costs. Automation in radiopharmaceutical preparation and quality control is also making isotope-based diagnostics more reproducible and scalable for broader clinical use. These innovations are collectively driving a transition toward more precise, personalized, and efficient diagnostic strategies using radioisotopes.

Why Is Clinical Demand for Radioisotope Imaging Rising Across Global Healthcare Systems?

Clinical demand for diagnostic radioisotopes is rising sharply across healthcare systems worldwide due to the increasing burden of chronic diseases, aging populations, and the growing emphasis on early and accurate diagnosis. In oncology, the global surge in cancer incidence is fueling demand for PET and SPECT imaging, which rely heavily on radioisotopes for tumor detection, staging, and therapy monitoring. Similarly, the rising prevalence of cardiovascular diseases is driving the need for nuclear stress tests and myocardial perfusion imaging using isotopes like Rubidium-82 and Thallium-201. In neurology, the increase in neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases has led to greater utilization of radioisotopes that can detect early pathological changes at the molecular level. Furthermore, the widespread adoption of precision medicine and targeted therapy approaches necessitates companion diagnostics that often involve radiolabeled agents to confirm disease presence and predict treatment response. Diagnostic radioisotopes are also being increasingly integrated into outpatient and ambulatory settings due to the development of compact, mobile imaging systems and simplified radiotracer protocols. In emerging markets, improvements in nuclear medicine infrastructure and growing healthcare expenditure are accelerating the adoption of radioisotope diagnostics. With clinicians and policymakers placing more value on timely, non-invasive, and accurate diagnostics, the clinical demand for radioisotopes is expected to rise substantially over the coming years.

What Are the Key Drivers Accelerating Global Growth in the Diagnostic Radioisotopes Market?

The growth in the diagnostic radioisotopes market is driven by a convergence of medical, technological, regulatory, and economic factors that reflect the increasing role of molecular imaging in precision healthcare. One of the most important drivers is the rising global burden of cancer, cardiovascular disease, and neurodegenerative disorders-conditions for which early and accurate diagnosis dramatically improves patient outcomes. The continued shift toward value-based healthcare models is also pushing providers to adopt diagnostic methods that can inform treatment decisions early, reduce unnecessary procedures, and optimize therapeutic efficacy. Expansion in cyclotron and radiopharmaceutical production capabilities is improving isotope accessibility, while ongoing investment in nuclear medicine infrastructure, especially in Asia-Pacific and Latin America, is opening new markets. Regulatory agencies like the FDA and EMA are accelerating the approval pathways for radiopharmaceuticals, particularly those developed as companion diagnostics for novel therapeutics. Moreover, strategic collaborations between pharmaceutical companies and diagnostic developers are advancing the theranostics field, where radioisotopes are used to select and monitor targeted therapies. Educational initiatives and clinical training programs are also helping bridge the talent gap in nuclear medicine, further supporting adoption. As global health systems strive for earlier intervention, lower healthcare costs, and personalized patient care, diagnostic radioisotopes are positioned as a critical enabler of the next generation of medical imaging and disease management.

SCOPE OF STUDY:

The report analyzes the Diagnostic Radioisotopes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Radioisotope Type (Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, Other Radioisotope Types); Diagnostic Radioisotope (SPECT, PET, Beta Emitters); Application (Diagnostic, Therapeutic); End-Use (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging S.p.A.
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion (Canada) Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Diagnostic Radioisotopes - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growth in Molecular Imaging and Nuclear Medicine Throws the Spotlight on Diagnostic Radioisotope Demand
  • Rising Prevalence of Cancer and Cardiac Disorders Fuels Use of SPECT and PET Tracers
  • Aging Infrastructure and Reactor Downtime Challenges Create Opportunities for Cyclotron-Based Isotope Production
  • Regulatory Approvals of New PET Tracers Accelerate Adoption in Oncology, Neurology, and Cardiology
  • Push for Personalized Imaging Protocols Spurs Use of Radiolabeled Biomarkers in Patient Stratification
  • Growth in Theranostics Fuels Convergence of Diagnostic and Therapeutic Isotopes in Hybrid Applications
  • Global Shortage of Molybdenum-99 Highlights Demand for Diversified Isotope Sourcing Strategies
  • Investment in Generator-Based Delivery Systems Supports On-Site Production for Smaller Facilities
  • Rise in Outpatient Nuclear Imaging Clinics Drives Use of Short Half-Life Isotopes with Quick Turnaround
  • Integration with AI and Quantitative Imaging Analytics Enhances Data Interpretation in Radioisotope Scans
  • Push for Low-Radiation Dose Imaging Accelerates Development of High-Specificity Tracers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diagnostic Radioisotopes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Technetium-99m by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Thallium-201 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Gallium-67 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Iodine-123 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for FDG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Rubidium-82 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Radioisotope Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for PET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION